STTK · TickerCove

STTKShattuck Labs, Inc.Healthcare · Biotechnologyas of 2026-09-16

Horizon

Issued 2026-09-16 at $5.88 · now $5.88 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, STTK has typically landed between $3.84 and $9.20 — a range of −34.8% to +56.4% from the issuance price $5.88.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.

Actual close
Typical path (median)
Middle 50% of outcomes
90% range

1,467 overlapping 1 month windows · 2020-10-09 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($5.88) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

52-week range$5.88 · 65% of range

$1.77 low$8.06 high

Trailing 52 weeks to 2026-09-16 — factual context, not a signal.

Base rate up · monthiClimatology base rate that a US-listed stock rises over a month, with its 90% CI and ≈1,408 effective observations. Not a call on this stock — we have no evidence its odds differ.

53.9%

90% CI 51.7%–56.1%

Distribution · month iiThe price-anchored range: typical move (median), and the p90 downside/upside — 90% of similar periods stayed inside these. Ranges, not a prediction of direction.

−4.0%

typical move · IQR 32.0%

−34.8%worst (p90)+56.4%best (p90)

Insider convictioniOpen-market common-stock purchases by company insiders in the last 90 days (grants and option exercises excluded). Historical tendency, not advice — detail below.

conviction buys

0 open-market sales

Congress disclosuresiRecent disclosed congressional trades for this company. Purchase clusters (≥2 members buying within 90 days) historically preceded a modestly higher forward return (+32 bp/mo in 2022–2026, +45 bp/mo in 2015–2021) — a descriptive tendency, not a forecast input. Detail below.

0 buys · 0 sells · 0 members

cluster tilt persisted, ~halved after 2021

Where STTK has typically landed a month from the 2026-09-16 close of $5.88 — the range is history, not a prediction.

now $5.88 (+0.0%)
typical $5.64 (-4.0%)
middle 50% $4.7–$6.58
90% range $3.84–$9.2

Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,467 windows spanning 2020-10-09 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.

Start	Return	Max drop	Max rise
3 worst
2024-09-06	−67.7%	−67.7%	+10.6%
2024-09-20	−66.6%	−69.8%	+3.5%
2024-09-05	−65.4%	−65.4%	+9.6%
3 best
2023-12-05	+387.2%	+0.0%	+387.2%
2023-12-11	+350.2%	+0.0%	+382.8%
2023-12-07	+327.5%	−11.4%	+327.5%

1,467 overlapping windows · 2020-10-09 – 2026-09-16 · not cherry-picked

Seasonality · by month i

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.

Jan

50%

+15.2%

n=6

Feb

50%

−3.9%

n=6

Mar

33%

−7.2%

n=6

Apr

83%

+8.9%

n=6

May

17%

−17.6%

n=6

Jun

67%

+1.5%

n=6

Jul

33%

−7.9%

n=6

Aug

17%

−2.7%

n=6

Sep

17%

+12.4%

n=6

Oct

20%

−16.8%

n=5

Nov

50%

−2.1%

n=6

Dec

100%

+65.7%

n=6

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Date	Person	Role	Action	Shares @ price	Value	Ownership Δ	vs S&P 1m	vs S&P 6m	Owned after	Filing
2026-07-02	Shukla Abhinav A.	officer	Sale	410 @ $7.01	$3K	−0.5% of holding	+1.7%	not yet — horizon still open	86,380	Form 4 · filed 5 days after the trade
2026-07-01	Shukla Abhinav A.	officer	Sale	100 @ $7.07	$707	−0.1% of holding	+8.4%	not yet — horizon still open	86,380	Form 4 · filed 1 day after the trade
2026-06-30	Pandite Arundathy N.	officer	Sale	30,000 @ $7.01	$210K	−18.0% of holding	+4.3%	not yet — horizon still open	136,219	Form 4 · filed 2 days after the trade
2026-06-30	Shukla Abhinav A.	officer	Sale	23,365 @ $7.08	$165K	−21.3% of holding	+4.3%	not yet — horizon still open	86,380	Form 4 · filed 2 days after the trade
2026-06-11	Ashiya Mona	director	Purchase	1,041,667	—	+4.1% of holding	+48.3%	not yet — horizon still open	26,519,541	Form 4 · filed 4 days after the trade
2026-06-11	Ashiya Mona	director	Purchase	208,333	—	+4.1% of holding	+48.3%	not yet — horizon still open	5,303,908	Form 4 · filed 4 days after the trade
2026-06-11	ORBIMED ADVISORS LLC	director	Purchase	1,041,667	—	+4.1% of holding	+48.3%	not yet — horizon still open	26,519,541	Form 4 · filed 4 days after the trade
2026-06-11	ORBIMED ADVISORS LLC	director	Purchase	208,333	—	+4.1% of holding	+48.3%	not yet — horizon still open	5,303,908	Form 4 · filed 4 days after the trade
2026-06-11	ORBIMED ADVISORS LLC	director	Purchase	1,041,667	—	+4.1% of holding	+48.3%	not yet — horizon still open	26,519,541	Form 4 · filed 4 days after the trade
2026-06-11	ORBIMED ADVISORS LLC	director	Purchase	208,333	—	+4.1% of holding	+48.3%	not yet — horizon still open	5,303,908	Form 4 · filed 4 days after the trade
2026-06-11	ORBIMED ADVISORS LLC	director	Purchase	1,041,667	—	+4.1% of holding	+48.3%	not yet — horizon still open	26,519,541	Form 4 · filed 4 days after the trade
2026-06-11	ORBIMED ADVISORS LLC	director	Purchase	208,333	—	+4.1% of holding	+48.3%	not yet — horizon still open	5,303,908	Form 4 · filed 4 days after the trade
2026-06-11	ORBIMED ADVISORS LLC	director	Purchase	1,041,667	—	+4.1% of holding	+48.3%	not yet — horizon still open	26,519,541	Form 4 · filed 4 days after the trade
2026-06-11	ORBIMED ADVISORS LLC	director	Purchase	208,333	—	+4.1% of holding	+48.3%	not yet — horizon still open	5,303,908	Form 4 · filed 4 days after the trade
2026-06-11	Ashiya Mona	director	Purchase	1,041,667	—	+4.1% of holding	+48.3%	not yet — horizon still open	26,519,541	Form 4 · filed 4 days after the trade
2026-06-11	Ashiya Mona	director	Purchase	208,333	—	+4.1% of holding	+48.3%	not yet — horizon still open	5,303,908	Form 4 · filed 4 days after the trade
2026-06-09	SIEGALL CLAY B	director	Purchase	62,500 @ $4.00	$250K	+24.4% of holding	+52.8%	not yet — horizon still open	318,608	Form 4 · filed 2 days after the trade
2026-05-12	Pandite Arundathy N.	officer	Sale	30,000 @ $6.61	$198K	−15.3% of holding	−36.8%	not yet — horizon still open	166,219	Form 4 · filed 2 days after the trade
2026-05-12	Shukla Abhinav A.	officer	Sale	2,032 @ $7.01	$14K	−2.4% of holding	−36.8%	not yet — horizon still open	81,258	Form 4 · filed 2 days after the trade
2025-08-25	Ashiya Mona	director	Purchase	5,255,106 @ $0.87	$4.6M	ownership Δ n/a	+133.3%	+299.1%	5,255,106	Form 4 · filed 8 days after the trade
2025-08-25	ORBIMED ADVISORS LLC	director	Purchase	5,255,106 @ $0.87	$4.6M	ownership Δ n/a	+133.3%	+299.1%	5,255,106	Form 4 · filed 8 days after the trade
2025-08-25	ORBIMED ADVISORS LLC	director	Purchase	1,051,021 @ $0.87	$912K	ownership Δ n/a	+133.3%	+299.1%	1,051,021	Form 4 · filed 8 days after the trade
2025-08-25	Ashiya Mona	director	Purchase	1,051,021 @ $0.87	$912K	ownership Δ n/a	+133.3%	+299.1%	1,051,021	Form 4 · filed 8 days after the trade
2025-08-25	ORBIMED ADVISORS LLC	director	Purchase	2,022,277	—	ownership Δ n/a	+133.3%	+299.1%	2,022,277	Form 4 · filed 8 days after the trade
2025-08-25	ORBIMED ADVISORS LLC	director	Purchase	15,366,490	—	ownership Δ n/a	+133.3%	+299.1%	15,366,490	Form 4 · filed 8 days after the trade
2025-08-25	ORBIMED ADVISORS LLC	director	Purchase	3,073,298	—	ownership Δ n/a	+133.3%	+299.1%	3,073,298	Form 4 · filed 8 days after the trade
2025-08-25	ORBIMED ADVISORS LLC	director	Purchase	2,022,277	—	ownership Δ n/a	+133.3%	+299.1%	2,022,277	Form 4 · filed 8 days after the trade
2025-08-25	ORBIMED ADVISORS LLC	director	Purchase	15,366,490	—	ownership Δ n/a	+133.3%	+299.1%	15,366,490	Form 4 · filed 8 days after the trade
2025-08-25	ORBIMED ADVISORS LLC	director	Purchase	3,073,298	—	ownership Δ n/a	+133.3%	+299.1%	3,073,298	Form 4 · filed 8 days after the trade
2025-08-25	ORBIMED ADVISORS LLC	director	Purchase	15,366,490	—	ownership Δ n/a	+133.3%	+299.1%	15,366,490	Form 4 · filed 8 days after the trade
2025-08-25	ORBIMED ADVISORS LLC	director	Purchase	3,073,298	—	ownership Δ n/a	+133.3%	+299.1%	3,073,298	Form 4 · filed 8 days after the trade
2025-08-25	Ashiya Mona	director	Purchase	10,111,384	—	ownership Δ n/a	+133.3%	+299.1%	10,111,384	Form 4 · filed 8 days after the trade
2025-08-25	Ashiya Mona	director	Purchase	2,022,277	—	ownership Δ n/a	+133.3%	+299.1%	2,022,277	Form 4 · filed 8 days after the trade
2025-08-25	Ashiya Mona	director	Purchase	15,366,490	—	ownership Δ n/a	+133.3%	+299.1%	15,366,490	Form 4 · filed 8 days after the trade
2025-08-25	Ashiya Mona	director	Purchase	3,073,298	—	ownership Δ n/a	+133.3%	+299.1%	3,073,298	Form 4 · filed 8 days after the trade
2025-08-25	ORBIMED ADVISORS LLC	director	Purchase	10,111,384	—	ownership Δ n/a	+133.3%	+299.1%	10,111,384	Form 4 · filed 8 days after the trade
2025-08-25	ORBIMED ADVISORS LLC	director	Purchase	2,022,277	—	ownership Δ n/a	+133.3%	+299.1%	2,022,277	Form 4 · filed 8 days after the trade
2025-08-25	ORBIMED ADVISORS LLC	director	Purchase	15,366,490	—	ownership Δ n/a	+133.3%	+299.1%	15,366,490	Form 4 · filed 8 days after the trade
2025-08-25	ORBIMED ADVISORS LLC	director	Purchase	10,111,384	—	ownership Δ n/a	+133.3%	+299.1%	10,111,384	Form 4 · filed 8 days after the trade
2025-08-25	ORBIMED ADVISORS LLC	director	Purchase	10,111,384	—	ownership Δ n/a	+133.3%	+299.1%	10,111,384	Form 4 · filed 8 days after the trade
2025-08-25	ORBIMED ADVISORS LLC	director	Purchase	10,111,384	—	ownership Δ n/a	+133.3%	+299.1%	10,111,384	Form 4 · filed 8 days after the trade
2025-08-25	ORBIMED ADVISORS LLC	director	Purchase	2,022,277	—	ownership Δ n/a	+133.3%	+299.1%	2,022,277	Form 4 · filed 8 days after the trade
2025-08-25	ORBIMED ADVISORS LLC	director	Purchase	3,073,298	—	ownership Δ n/a	+133.3%	+299.1%	3,073,298	Form 4 · filed 8 days after the trade
2024-12-04	Redmile Group, LLC	director	Purchase	133,371 @ $1.25	$167K	+2.5% of holding	+3.3%	−7.1%	5,539,724	Form 4 · filed 2 days after the trade
2024-12-04	Redmile Group, LLC	director	Sale	133,371 @ $1.25	$167K	−2.4% of holding	+3.3%	−7.1%	5,406,353	Form 4 · filed 2 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

113 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

Date	Person	Role	Action	Shares	Owned after	Filing
2026-07-06	Shukla Abhinav A.	officer	Option exercise	12,153	98,533	Form 4
2026-07-06	Shukla Abhinav A.	officer	Option exercise	12,153	14,140	Form 4
2026-07-02	Shukla Abhinav A.	officer	Option exercise	410	86,790	Form 4
2026-07-02	Shukla Abhinav A.	officer	Option exercise	410	26,293	Form 4
2026-07-01	Shukla Abhinav A.	officer	Option exercise	100	86,480	Form 4
2026-07-01	Shukla Abhinav A.	officer	Option exercise	100	26,703	Form 4
2026-06-30	Shukla Abhinav A.	officer	Option exercise	23,365	109,745	Form 4
2026-06-30	Shukla Abhinav A.	officer	Option exercise	23,365	26,803	Form 4
2026-06-08	ORBIMED ADVISORS LLC	director	Conversion	3,073,298	5,095,575	Form 4
2026-06-08	Ashiya Mona	director	Conversion	15,366,490	25,477,874	Form 4
2026-06-08	Ashiya Mona	director	Conversion	3,073,298	5,095,575	Form 4
2026-06-08	Ashiya Mona	director	Conversion	15,366,490	0	Form 4
2026-06-08	Ashiya Mona	director	Conversion	3,073,298	0	Form 4
2026-06-08	ORBIMED ADVISORS LLC	director	Conversion	15,366,490	25,477,874	Form 4
2026-06-08	ORBIMED ADVISORS LLC	director	Conversion	15,366,490	0	Form 4
2026-06-08	ORBIMED ADVISORS LLC	director	Conversion	3,073,298	0	Form 4
2026-06-08	ORBIMED ADVISORS LLC	director	Conversion	15,366,490	25,477,874	Form 4
2026-06-08	ORBIMED ADVISORS LLC	director	Conversion	3,073,298	5,095,575	Form 4
2026-06-08	ORBIMED ADVISORS LLC	director	Conversion	15,366,490	0	Form 4
2026-06-08	ORBIMED ADVISORS LLC	director	Conversion	3,073,298	0	Form 4
2026-06-08	ORBIMED ADVISORS LLC	director	Conversion	15,366,490	25,477,874	Form 4
2026-06-08	ORBIMED ADVISORS LLC	director	Conversion	3,073,298	5,095,575	Form 4
2026-06-08	ORBIMED ADVISORS LLC	director	Conversion	15,366,490	0	Form 4
2026-06-08	ORBIMED ADVISORS LLC	director	Conversion	3,073,298	0	Form 4
2026-06-08	Ashiya Mona	director	Conversion	15,366,490	25,477,874	Form 4
2026-06-08	Ashiya Mona	director	Conversion	3,073,298	5,095,575	Form 4
2026-06-08	Ashiya Mona	director	Conversion	15,366,490	0	Form 4
2026-06-08	Ashiya Mona	director	Conversion	3,073,298	0	Form 4
2026-06-08	ORBIMED ADVISORS LLC	director	Conversion	15,366,490	25,477,874	Form 4
2026-06-08	ORBIMED ADVISORS LLC	director	Conversion	3,073,298	5,095,575	Form 4
2026-06-08	ORBIMED ADVISORS LLC	director	Conversion	15,366,490	0	Form 4
2026-06-08	ORBIMED ADVISORS LLC	director	Conversion	3,073,298	0	Form 4
2026-05-29	Baker Daniel G.	director	Award / grant	81,000	81,000	Form 4
2026-05-29	Ashiya Mona	director	Award / grant	81,000	81,000	Form 4
2026-05-29	Boudreau Helen M	director	Award / grant	81,000	81,000	Form 4
2026-05-29	Gibson Neil W	director	Award / grant	81,000	81,000	Form 4
2026-05-29	Golumbeski George	director	Award / grant	81,000	81,000	Form 4
2026-05-29	SIEGALL CLAY B	director	Award / grant	81,000	81,000	Form 4
2026-05-22	SIEGALL CLAY B	director	Award / grant	128,054	256,108	Form 4
2026-05-22	SIEGALL CLAY B	director	Option exercise	128,054	0	Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Resolves in i

28d remaining

2026-09-173% elapsed2026-10-15

Logged immutably 2026-09-17; scored automatically on 2026-10-15 — no edits, ever.

Earnings & context analysis

These panels are being prepared. They are generated by multiple language models, checked, and stored before display — never written live for a page view. Until a model panel has been generated and reviewed for a company, nothing is shown here, honestly, rather than a placeholder.

Calibration i

Every forecast is logged when made and scored when the month is up. The record is shown from the day it starts — young and honest.

How scoring works →

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

Reported insider & political trades

Congressional disclosures

Seasonality · by month i